Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.
A new brand is seeking 10 U.S.-based individuals aged 25+ experiencing hair loss to test a topical product containing GHK-Cu and Acetyl Tetrapeptide-3. Participants must not be using other treatments like finasteride or minoxidil and will provide feedback and photos.
User started finasteride in Oct 2021 and experienced reduced shedding and side effects. Saw improvements in months 3-5, but worsening in months 11-13, and asks for advice on next steps.
Male pattern baldness and diffuse thinning can both be forms of androgenetic alopecia (AGA), and it's important to consult a doctor for proper diagnosis. Treatments like Minoxidil, Finasteride, and biotin are discussed, but their effectiveness varies, and side effects are a concern.
An 18-year-old is experiencing hair loss and has been using topical minoxidil consistently for over a year, with some improvement in hair density. They tried switching to a combination of topical finasteride and minoxidil but experienced possible side effects, so they returned to using only minoxidil, along with biotin and dermarolling, and are seeking advice on whether finasteride might still be effective for them.
Finasteride worked better for frontal scalp hair loss, while dutasteride helped the crown and mid-scalp but worsened the frontal area. The user shared personal experiences and invited open dialogue.
A 23-year-old male showed hair regrowth after using finasteride and minoxidil daily for three months, with no significant side effects. Others shared their experiences and discussed side effects and photo lighting differences.
The user documented their hair treatment journey from 2018 to 2025, primarily using dutasteride after initially trying topical minoxidil in 2023. They saw noticeable regrowth in the temple area after two months and experienced some shedding after stopping minoxidil.
The conversation discusses various hair loss treatments, including Breezula, KX826, and PP405, with mixed opinions on their effectiveness compared to finasteride and minoxidil. Some users express skepticism about the new treatments, while others remain hopeful about future developments.
The individual is experiencing hair thinning primarily at the front/middle of their scalp and is seeking to identify the type of hair loss they have. They already use treatments like oral Minoxidil, topical Finasteride, Tretinoin gel, dermarolling, and various oils and shampoos.
Hair loss may be linked to blood flow and inflammation, with treatments like Minoxidil, finasteride, and quercetin being discussed. The conversation also mentions the role of 5AR enzyme distribution in hair follicles.
The conversation discusses the best vehicle for topical dutasteride, comparing Trichosol, Transcutol, and a gel version. It also mentions using Transcutol with ethanol to enhance transdermal delivery of Bimatoprost.
Switching from Accord to Aurobindo finasteride initially reduced hair shedding, but after three months, shedding increased again. Users discuss varying experiences with different finasteride brands, with some suggesting brand differences may not matter.
The conversation discusses potential future hair loss treatments, including SCUBE3, hair follicle cloning, and GT20029, with mentions of past disappointments like CosmeRNA and hopes for treatments like Verteporfin for infinite donor hair.
The user treated their hair loss with daily finasteride, nightly minoxidil, weekly derma rolling, biotin, and ketoconazole shampoo. They believe consistency is key and that micro needling and minoxidil were the most effective.
A user noticed their hair became curlier after a year on finasteride 1.25mg daily, but it returned to wavy when taken every other day. They are questioning if this change affects the treatment's effectiveness and are seeking similar experiences.
An 18-year-old male using minoxidil and finasteride is experiencing increased hair loss, possibly due to a shedding phase from finasteride. He also takes zinc, magnesium, calcium, and vitamin C, and is concerned about hair loss from his temples.
A 22-year-old with 4c hair is considering a hair transplant to address traction alopecia caused by braid extensions. They have tried derma stamping, oils, and minoxidil but stopped due to side effects.
The user is concerned about whether their hair styling is causing thinning or if it's natural. They are considering treatments like Minoxidil, finasteride, or RU58841 for hair loss.
The conversation discusses using topical dutasteride with a dermapen for hair loss treatment. The user is deciding between liposomal and mesosomal formulations for this purpose.
The conversation discusses the variability in effectiveness of medications, including finasteride, and questions whether different manufacturers impact results. The user suggests sharing successful brands to help others identify effective options.
A user is interested in seeing scalp tattoos as a response to hair loss, specifically looking for creative designs rather than scalp micropigmentation. They are considering this approach for their own Norwood 5 hair loss situation.
The user is unsure if their hair appears fuller due to a haircut or actual regrowth, but believes there is increased density and small new hairs. They are using 1 mg finasteride daily, 2.5 mg minoxidil daily, and Nizoral frequently for hair loss treatment.
Trans woman experiences hair thinning despite low testosterone and treatments like finasteride and microneedling. Possible causes discussed include past eating disorder and current stack of medications and supplements.
The conversation is about organizing hair regrowth results using a standard format in a single post for easier access. Treatments mentioned include oral minoxidil, oral finasteride, and dermarolling.
PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.